Compare ALEMBIC with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs ASTRAZENECA PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC ASTRAZENECA PHARMA ALEMBIC/
ASTRAZENECA PHARMA
 
P/E (TTM) x 78.7 125.8 62.5% View Chart
P/BV x 6.8 38.5 17.6% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 ALEMBIC   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
ASTRAZENECA PHARMA
Mar-18
ALEMBIC/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs721,278 5.6%   
Low Rs34883 3.8%   
Sales per share (Unadj.) Rs4.7228.4 2.1%  
Earnings per share (Unadj.) Rs6.110.4 58.9%  
Cash flow per share (Unadj.) Rs6.216.3 38.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.798.8 41.2%  
Shares outstanding (eoy) m267.0325.00 1,068.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.7 238.2%   
Avg P/E ratio x8.7104.2 8.3%  
P/CF ratio (eoy) x8.566.4 12.8%  
Price / Book Value ratio x1.310.9 11.9%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,13927,008 52.4%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m2071,535 13.5%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m1,2555,710 22.0%  
Other income Rs m370123 302.2%   
Total revenues Rs m1,6255,833 27.9%   
Gross profit Rs m111463 24.0%  
Depreciation Rs m38147 25.6%   
Interest Rs m20-   
Profit before tax Rs m442438 100.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24179 13.4%   
Profit after tax Rs m1,630259 629.0%  
Gross profit margin %8.98.1 109.2%  
Effective tax rate %5.440.8 13.3%   
Net profit margin %129.84.5 2,861.6%  
BALANCE SHEET DATA
Current assets Rs m1,8673,209 58.2%   
Current liabilities Rs m5912,070 28.6%   
Net working cap to sales %101.620.0 509.3%  
Current ratio x3.21.6 203.7%  
Inventory Days Days9472 130.3%  
Debtors Days Days7435 210.6%  
Net fixed assets Rs m1,791790 226.6%   
Share capital Rs m53450 1,068.2%   
"Free" reserves Rs m10,3242,419 426.7%   
Net worth Rs m10,8582,469 439.7%   
Long term debt Rs m410-   
Total assets Rs m11,5914,605 251.7%  
Interest coverage x260.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.11.2 8.7%   
Return on assets %14.15.6 250.2%  
Return on equity %15.010.5 143.1%  
Return on capital %15.217.7 85.6%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19300 6.5%   
Fx outflow Rs m2642,015 13.1%   
Net fx Rs m-244-1,715 14.2%   
CASH FLOW
From Operations Rs m23688 268.3%  
From Investments Rs m-224-94 239.3%  
From Financial Activity Rs m-27NA-  
Net Cashflow Rs m-15-6 259.6%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 0.3 66.7%  
FIIs % 9.7 15.7 61.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 9.1 286.8%  
Shareholders   54,701 12,856 425.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT PHARMOVA   BIOCON   

Compare ALEMBIC With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Tata Steel Jumps 4% Post Q4 Results(09:30 am)

Asian share markets rose in early trade today after data released overnight showed the US services sector added hundreds of thousands of jobs last month.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 6, 2021 10:46 AM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS